XVIVO Perfusion AB (publ) issue of warrants of series 2019/2021 fully subscribed

The annual general meeting in XVIVO Perfusion AB (publ) (”XVIVO”) on 25 April 2019 resolved to issue up to 351,000 share warrants of series 2019/2021 to employees of XVIVO and XVIVO’s Swedish subsidiaries, with a date of employment on or before 18 October 2019. A total of 351 000 warrants were subscribed which means that the issue has been subscribed in full.

Each warrant entitles to subscribe for one new share in XVIVO for a subscription price corresponding to 150 percent of the volume weighted average price for XVIVO´s shares quoted on Nasdaq Stockholm for each trading day during (i) the period 2 May 2019 – 15 May 2019 for persons employed 1 May 2019, and (ii) the 10 previous trading days before the date of employment for persons employed during the period 2 May 2019 – 18 October 2019. The warrants may be exercised to subscribe for new shares at the share price of SEK 278.91 during the period 3 May 2021 – 31 May 2021.

The warrants have been issued at market value calculated according to the Black & Scholes valuation model.

If all warrants are utilized to subscribe for new shares, XVIVO’s share capital will increase by SEK 8,971.13, corresponding to a dilution of approximately 1.3 percent of the total number of shares and votes in XVIVO.

23 October 2019
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of the contact person set out above, at 1:00 pm CET on October 23, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.